Navigation Links
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
Date:1/6/2009

ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational. The contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is part of NIAID's clinical resource infrastructure to accelerate Phase 1 studies of promising clinical stage drugs or vaccines that address emerging and re-emerging infectious tropical diseases and bioweapon pathogens. The Phase 1B clinical study of SQ109 should be initiated in Q1 2009.

SQ-109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. The Phase 1B study will assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

"This is absolutely the best of both worlds for Sequella," commented Dr. Carol Nacy, Sequella CEO. "We again successfully competed for support from our most valued funding partner, NIAID, while retaining the capacity to work with the same industry-leading contract research organization, Quintiles Transnational, that conducted our first-in-human Phase 1A trial for SQ109.

The trial will be conducted at the Overland Park Quintiles Transnational Phase 1 facility in Lenexa, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for diseases of epidemic pot
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
2. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
5. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
6. Novel Compound Shows Promise for Treatment of Alcoholism
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
9. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
10. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
11. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... LONDON , Aug. 27, 2014 /PRNewswire/ ... research report: Collaborative R&D Terms ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The ... Biotech and Diagnostics report provides comprehensive understanding ... deals and agreements entered into by the ...
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html ... soft tissues are the mass of cells that ... types of orthopedic soft tissues such as tendons, ...
Breaking Medicine Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5
(Date:8/28/2014)... (PRWEB) August 28, 2014 Now in its ... that was started in 2011 by two brain aneurysm survivors. ... much needed awareness, provide education to help increase early detection ... impacted by a brain aneurysm. We hope that you will ... worthy cause at the 4th Annual Step for Hope Run/ ...
(Date:8/28/2014)... MMAR Medical is pleased to announce ... for regular customers to enjoy several perks and benefits ... a wholesale license. It’s a great choice for independent ... others who regularly purchase medical braces but could use ... own active lifestyle or those of your club, group ...
(Date:8/28/2014)... The revenue cycle process touches on ... time a patient books an appointment with a physician’s ... payments for services rendered to the healthcare provider. ... has the RCM process down to a science. Over ... common place in nearly every healthcare facility around the ...
(Date:8/28/2014)... August 28, 2014 UniVoIP, Inc, a ... Segundo, CA, today announced that they have been certified ... Los Angeles Local Small Business Enterprise (Local SBE) Preference ... certified by the state of California and LA county ... Cloud-hosted Telephony Solution to governmental agencies throughout the ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
Breaking Medicine News(10 mins):Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:MMAR Medical Announces Customer Membership Program 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Cloud PBX Provider UniVoIP Gets Certified by the State of California and the County of Los Angeles Under the Local Small Business Enterprise (SBE) Preference Program 2Health News:William H. Simon Launches New Marketing Campaign for Book 2
... - Sunrise Senior Living and Conrad Properties Partner to Redefine Landmark ... Property Exclusively For Seniors ... SRZ ), an operator of more than 450 senior living communities,worldwide, ... 23- story Clayton on the Park hotel and apartments into an,exclusive ...
... entire Texas,Medical Board (TMB) and its officials have been ... Physicians and Surgeons (AAPS). The complaint,filed this week in ... performing its official duties, specifically:, 1. Manipulation of ... Violation of due process;, 4. Breach of privacy; ...
... Virginia, Dec. 21 Echo Healthcare,Acquisition Corp. ("Echo" ... check company, announced at its special meeting of ... Friday, December 28, 2007 for,stockholders to vote on ... ("XLNT") and the related matters set forth in ...
... Pa. and KENILWORTH, N.J., Dec. 21 ,Centocor, ... ) today announced,they have revised their 1998 ... of both REMICADE(R),(infliximab), an anti-tumor necrosis factor ... golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, which ...
... will ensure consumers, interests are considered, protected, HARRISBURG, ... are protected, acting Insurance Commissioner Joel,Ario today announced that ... part of its review of the proposed consolidation of,Independence ... is to see that consumers would be protected in,any ...
... team says , FRIDAY, Dec. 21 (HealthDay News) -- People with ... a study that adds to growing evidence of a link between ... analyzed leg and torso measurements, as well as blood samples, from ... , The blood samples were checked for levels of four liver ...
Cached Medicine News:Health News:Sunrise to Unveil New Residence for Seniors at Clayton on the Park 2Health News:Doctors' Group Sues Texas Medical Board for Misconduct; Cites Institutional Culture of Retaliation & Intimidation 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2Health News:Shorter Legs Might Boost Liver Risks 2
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
2 mm x 0.75 mm. Overall length: 125 mm, 4.9 inches....
...
Medicine Products: